Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Genomics of Hematologic Cancers
share announcement

Genomics of Hematologic Cancers

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".

Deadline for manuscript submissions: closed (31 January 2024) | Viewed by 3676

Special Issue Editors

Dr. Aneta Szudy-Szczyrek

E-Mail Website
Guest Editor
Chair and Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, 20-081 Lublin, Poland
Interests: haematological neoplasms; multiple myeloma; mastocytosis; biomarkers; molecular biology; genetics; epigenetics; predictive factors; prognostic factors; targeted therapy
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Marek Hus

E-Mail Website
Guest Editor
Department of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, 20-081 Lublin, Poland
Interests: haematological neoplasms; multiple myeloma; leukemia; lymphoma; mastocytosis; biomarkers; molecular biology; genetics; epigenetics; predictive factors; prognostic factors; targeted therapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Hematologic malignancies account for 10% of all cancers around the world and have become more frequent over the past years. Despite the huge progress associated with the improvements in hematologic molecular diagnostics and the development of targeted therapies such as kinase inhibitors, monoclonal antibodies, CART-cells and bispecific antibodies, most hematologic cancers remain incurable diseases.

Applying genomic analysis based on high-throughput sequencing technologies has been rapidly expanding our understanding of cancer origin and complexity, giving us more reliable information on its progression, metastases, and survival. Genome sequencing has been provided to know a full spectrum of genetic mutations that trigger or contribute to cancer development and how cancer evolves in response to treatments.

In this way, cancer-genome profiling is currently widely applied in routine clinical practice and has enabled the detection of predictive biomarkers of response for treatment.

This Special Issue is devoted to the application of genomics in identifying new cancer targets and developing new targeted therapies in hematologic cancers.

Dr. Aneta Szudy-Szczyrek
Prof. Dr. Marek Hus
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

 

Keywords

  • genomics
  • cancer
  • haematological malignancy
  • leukemia
  • lymphoma
  • myeloma
  • whole-genome sequencing
  • precision cancer medicine
  • target gene
  • targeted therapy
  • personalized medicine

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

16 pages, 1475 KiB  
Article
Association of Chromosome 17 Aneuploidy, TP53 Deletion, Expression and Its rs1042522 Variant with Multiple Myeloma Risk and Response to Thalidomide/Bortezomib Treatment
by Sylwia Popek-Marciniec, Wojciech Styk, Magdalena Wojcierowska-Litwin, Sylwia Chocholska, Aneta Szudy-Szczyrek, Marzena Samardakiewicz, Grazyna Swiderska-Kolacz, Joanna Czerwik-Marcinkowska and Szymon Zmorzynski
Cancers 2023, 15(19), 4747; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers15194747 - 27 Sep 2023
Viewed by 951
Abstract
Multiple myeloma (MM) is a multifactorial genetic disorder caused by interactive effects of environmental and genetic factors. The proper locus of the TP53 gene (17p13.1) and its protein is essential in genomic stability. The most common variant of the TP53 gene—p.P72R (rs1042522)—shows functional [...] Read more.
Multiple myeloma (MM) is a multifactorial genetic disorder caused by interactive effects of environmental and genetic factors. The proper locus of the TP53 gene (17p13.1) and its protein is essential in genomic stability. The most common variant of the TP53 gene—p.P72R (rs1042522)—shows functional variation. The aim of our study was a complex analysis of the TP53 p.P72R variant and TP53 gene expression in relation to chromosomal changes of the TP53 gene locus, as well as MM risk and outcome. Genomic DNA from 129 newly diagnosed MM patients was analyzed by methods of automated DNA sequencing (for TP53 variant analysis) and cIg-FISH (for chromosomal aberrations analysis). RNA was used in real-time PCR to determine the TP53 expression. In MM patients, the TP53 variant was not in Hardy–Weinberg equilibrium. The RR genotype was associated with lower MM risk (OR = 0.44, p = 0.004). A higher number of plasma cells was found in patients with RR genotype in comparison to those with PP + PR genotypes (36.74% vs. 28.30%, p = 0.02). A higher expression of the TP53 gene was observed in PP + PR genotypes vs. RR homozygote (p < 0.001), in smokers vs. non-smokers (p = 0.02). A positive Pearson’s correlation was found between the TP53 expression level and the number of plasma cells (r = 0.26, p = 0.04). The presence of chromosome 17 aberrations with or without TP53 locus did not affect the MM risk and outcome. Similar results were observed in the case of TP53 gene expression and the p.P72R variant. Full article
(This article belongs to the Special Issue Genomics of Hematologic Cancers)
►▼ Show Figures

Figure 1

Review

Jump to: Research

16 pages, 2252 KiB  
Review
Role of Non-Coding RNAs in Diagnosis, Prediction and Prognosis of Multiple Myeloma
by Maciej Dubaj, Karol Bigosiński, Aleksandra Dembowska, Radosław Mlak, Aneta Szudy-Szczyrek, Teresa Małecka-Massalska and Iwona Homa-Mlak
Cancers 2024, 16(5), 1033; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers16051033 - 2 Mar 2024
Viewed by 804
Abstract
Multiple myeloma (MM) is the second most common hematologic malignancy in the world and accounts for 15% of primary hemocytopathies, with an ever-increasing number of new cases. It is asymptomatic in 30% of instances; hence, the determination of highly sensitive and specific markers [...] Read more.
Multiple myeloma (MM) is the second most common hematologic malignancy in the world and accounts for 15% of primary hemocytopathies, with an ever-increasing number of new cases. It is asymptomatic in 30% of instances; hence, the determination of highly sensitive and specific markers is necessary to make a proper diagnosis. In the last 20 years, miRNAs, involved in regulating the expression of genes responsible for cell proliferation and differentiation, including tumor cells, have been identified as potential diagnostic and prognostic markers. The main aim of the following review was to outline the role of miRNAs in the diagnosis and prognosis of MM, considering their role in the pathogenesis of the disease and identifying their target genes and pathways. For this purpose, publications dating from 2013–2023 have been reviewed. Based on the available data, it is concluded that non-coding RNAs including miRNAs could be potential markers in MM. Furthermore, they may serve as therapeutic targets for certain drugs. Full article
(This article belongs to the Special Issue Genomics of Hematologic Cancers)
►▼ Show Figures

Figure 1

14 pages, 4553 KiB  
Review
Current Landscape of Genome-Wide Association Studies in Acute Myeloid Leukemia: A Review
by Richard J. Marrero and Jatinder K. Lamba
Cancers 2023, 15(14), 3583; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers15143583 - 12 Jul 2023
Cited by 3 | Viewed by 1519
Abstract
Acute myeloid leukemia (AML) is a clonal hematopoietic disease that arises from chromosomal and genetic aberrations in myeloid precursor cells. AML is one of the most common types of acute leukemia in adults; however, it is relatively rare overall, comprising about 1% of [...] Read more.
Acute myeloid leukemia (AML) is a clonal hematopoietic disease that arises from chromosomal and genetic aberrations in myeloid precursor cells. AML is one of the most common types of acute leukemia in adults; however, it is relatively rare overall, comprising about 1% of all cancers. In the last decade or so, numerous genome-wide association studies (GWAS) have been conducted to screen between hundreds of thousands and millions of variants across many human genomes to discover genetic polymorphisms associated with a particular disease or phenotype. In oncology, GWAS has been performed in almost every commonly occurring cancer. Despite the increasing number of studies published regarding other malignancies, there is a paucity of GWAS studies for AML. In this review article, we will summarize the current status of GWAS in AML. Full article
(This article belongs to the Special Issue Genomics of Hematologic Cancers)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop